Shares of Fate Therapeutics, Inc. (NASDAQ:FATE – Get Free Report) have earned a consensus recommendation of “Hold” from the twelve analysts that are currently covering the company, MarketBeat reports. One analyst has rated the stock with a sell rating, seven have issued a hold rating and four have assigned a buy rating to the company. The average 12-month target price among brokerages that have issued ratings on the stock in the last year is $6.90.
Several research analysts have issued reports on the company. Piper Sandler upgraded Fate Therapeutics from a “neutral” rating to an “overweight” rating and increased their price target for the stock from $4.00 to $6.00 in a report on Monday, June 17th. Needham & Company LLC reissued a “hold” rating on shares of Fate Therapeutics in a research note on Wednesday, August 14th. Finally, HC Wainwright reissued a “neutral” rating and issued a $5.00 price objective on shares of Fate Therapeutics in a research note on Thursday, August 22nd.
Read Our Latest Report on FATE
Hedge Funds Weigh In On Fate Therapeutics
Fate Therapeutics Price Performance
Shares of Fate Therapeutics stock opened at $3.64 on Thursday. Fate Therapeutics has a one year low of $1.63 and a one year high of $8.83. The stock’s 50-day moving average is $4.04 and its 200 day moving average is $4.50. The firm has a market cap of $414.35 million, a price-to-earnings ratio of -1.90 and a beta of 1.84.
Fate Therapeutics (NASDAQ:FATE – Get Free Report) last announced its quarterly earnings results on Tuesday, August 13th. The biopharmaceutical company reported ($0.33) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.47) by $0.14. The business had revenue of $6.77 million for the quarter, compared to analyst estimates of $1.47 million. Fate Therapeutics had a negative return on equity of 44.09% and a negative net margin of 1,426.67%. On average, sell-side analysts expect that Fate Therapeutics will post -1.73 EPS for the current fiscal year.
Fate Therapeutics Company Profile
Fate Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders.
Featured Articles
- Five stocks we like better than Fate Therapeutics
- Russell 2000 Index, How Investors Use it For Profitable Trading
- The Average 401k Balance by Age Explained
- 3 Monster Growth Stocks to Buy Now
- 3 Uranium Stocks To Gain as Microsoft Goes Nuclear to Power AI
- There Are Different Types of Stock To Invest In
- Biotech Boom Ahead? Key Stocks and ETFs to Watch Now
Receive News & Ratings for Fate Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fate Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.